Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by Showmi1on Sep 13, 2017 3:27pm

190 Views

Post# 26691772

RE:Halted

It is - nice bump in price. From what I read it works. Moving it to the Nasdeq should get us more volume - look at today. Maybe they will get the Bond or what ever and have a few hundred million in the bank.
Its great that this works for the children - not a huge market but seriously a huge step for children who already suffer with cancer not to have to suffer hearing loss

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload